Visa Suomi
Papers
2
Total Citations
38
H-Index
2
About
Visa Suomi is a leading researcher in the field of interventional oncology, with a primary focus on the development and clinical translation of MRI-guided transurethral ultrasound ablation (TULSA) for the treatment of localized prostate cancer. His major contributions center on establishing the safety, accuracy, and post-treatment imaging characteristics of this novel, minimally invasive therapeutic approach. In his highly cited 2019 feasibility study (30 citations), Dr. Suomi provided the first prospective assessment of lesion-targeted TULSA, demonstrating its potential for precise tumor ablation with acceptable toxicity. He further advanced the field by systematically characterizing the acute and subacute MRI findings following the procedure, offering critical insights for clinicians to accurately interpret post-ablation imaging and distinguish treatment effects from residual disease. This work is foundational for the clinical adoption of TULSA, helping to define the expected evolution of cell death and tissue response. Through these pioneering studies, Dr. Suomi has significantly shaped the understanding of image-guided focal therapy for prostate cancer, providing a roadmap for its safe and effective implementation.
Research Focus
Key Achievements
Top Papers
- 1
- 2